Table 2 The clinical characteristics of the 220 non-small cell lung cancer (NSCLC) patients
Variate | Number of patients [cases (%)] |
|---|---|
Total | 220 |
Age (years) | |
≤55 | 93 (42.3) |
>55 | 127 (57.7) |
Smoking status | |
Never | 95 (43.2) |
Ever | 125 (56.8) |
Gender | |
Male | 165 (75.0) |
Female | 55 (25.0) |
ECOG PS | |
0–1 | 39 (17.7) |
2 | 181 (82.3) |
Histological type | |
Adenocarcinoma | 108 (49.1) |
Squamous cell carcinoma | 112 (50.9) |
Stage | |
I–II | 8 (3.6) |
III–IV | 212 (96.4) |
Platinum-based drug | |
Cisplatin | 37(16.8) |
Carboplatin | 183 (83.2) |
Chemotherapy regimen | |
Platinum-gemcitabine | 112 (50.9) |
Platinum-pemetrexed | 68 (30.9) |
Platinum-paclitaxel | 23 (10.4) |
Platinum-docetaxel | 12 (5.5) |
Platinum-navelbine | 5 (2.3) |
Severe toxicity | |
Total | 79 (35.9) |
Hematologic toxicity | 55 (25.0) |
Gastrointestinal toxicity | 31 (14.1) |